A1 Refereed original research article in a scientific journal

B-cell receptor stereotyped subsets and outcome for patients with chronic lymphocytic leukemia in the HOVON 68 trial




AuthorsVojdeman F.J., Pedersen L.B., Te Raa D., Juvonen V., van Norden Y., Tjønnfjord G.E., Kimby E., Itälä-Remes M., Rosenquist R., Langerak A.W., Evers L.M., Zenz T., Walewski J., van Oers M.H.J., Geisler C.H., Kater A.P., Niemann C.U.

PublisherOAE Publishing Inc.

Publication year2021

JournalJournal of Translational Genetics and Genomics

Journal name in sourceJournal of Translational Genetics and Genomics

Volume5

Issue2

First page 182

Last page188

ISSN2578-5281

DOIhttps://doi.org/10.20517/jtgg.2021.03

Web address https://jtggjournal.com/article/view/4106

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/179588429


Abstract

Aim: We here assessed the impact of B-cell receptor stereotypy on progression-free survival (PFS) and overall survival in patients from the HOVON 68 trial.

Methods: Based on IGHV mutational analyses from participating centers in Sweden, Norway, Finland, Denmark, Poland, and the Netherlands, B-cell receptor stereotyped subsets were assigned using the ARResT/AssignSubsets software. Analysis for recurrent mutations was performed by next-generation sequencing by a 454-base platform. All other clinical data were extracted from the HOVON database by November 2016.

Results: In total, 178 out of 192 patients with sequences available were technically suitable for analysis. Thirty-eight patients (21%) were assigned to one of the 19 major subsets: Subset #2 (n = 12, 6.7%), Subset #8 (n = 7, 3.9%), Subset #6 (n = 6, 3.4%), and Subset #1 (n = 5, 2.8%). Other subsets found were: Subsets #3, #5, #31, and #64B. By November 2016, a PFS event had occurred for 150 patients (84%) and 79 patients (44%) had died. The median follow-up time for patients still alive was 78.9 months. Patients with UM-IGHV belonging to Subset #2 had significantly longer PFS than UM-IGHV 3-21-utilizing non-Subset #2 patients [UM-IGHV Subset #2 median PFS 61.3 months (n = 8) vs. UM-IGHV 3-21 non-Subset #2 median PFS 22.3 months (n = 6), P = 0.01]. Overall, no significant differences in PFS between groups were found for patients with M-IGHV.

Conclusion: In the HOVON 68 trial. Subset #2 patients had a good treatment outcome comparable to the outcome for non-high-risk patients with chronic lymphocytic leukemia following fludarabine-cyclophosphamide-rituximab-based treatment.


Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2024-26-11 at 23:41